纳尔克林公司以29亿美元收购索莱诺, 以增加肥胖药物Vykat XR. Neurocrine buys Soleno for $2.9B to add obesity drug Vykat XR.

通过收购Soleno Therapeutics公司, 将Vykat XR加入其投资组合. Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, or $53 per share, to add Vykat XR to its portfolio. 这种药物是FDA首次批准的治疗与普拉德-威利综合征相关的食物过多症, 罕见的遗传病因导致严重肥胖. This drug is the first FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome, a rare genetic condition causing severe obesity. 这一交易突显了朝着具有商业潜力,高增长的罕见疾病市场进行战略转变. The deal highlights a strategic shift toward high-growth rare disease markets with proven commercial potential.